Fax: (314) 362-7086
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer†‡§
Results from Cancer and Leukemia Group B Study 90006
Version of Record online: 22 SEP 2010
Copyright © 2010 American Cancer Society
Volume 117, Issue 3, pages 526–533, 1 February 2011
How to Cite
Picus, J., Halabi, S., Kelly, W. K., Vogelzang, N. J., Whang, Y. E., Kaplan, E. B., Stadler, W. M., Small, E. J. and for Cancer and Leukemia Group B (2011), A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer. Cancer, 117: 526–533. doi: 10.1002/cncr.25421
Presented at the 39th Annual Meeting of the American Society of Clinical Oncology; Chicago, Illinois; May 31 to June 3, 2003.
The following institutions participated in this study: Cancer and Leukemia Group B Statistical Office, Durham, NC (Stephen George, PhD); Christiana Care Health Services, Inc., Community Clinical Oncology Program (CCOP), Wilmington, Del (Stephen S. Grubbs, MD); Dana Farber Cancer Institute, Boston, Mass (Eric P. Winer, MD); Mount Sinai Medical Center, Miami, Fla (Rogerio Lilenbaum, MD); North Shore University Hospital, Manhasset, NY (Daniel R. Budman, MD); The Ohio State University Medical Center, Columbus, Ohio (Clara D. Bloomfield, MD); Rhode Island Hospital, Providence, RI (William Sikov, MD); Syracuse Hematology-Oncology Association CCOP, Syracuse, NY (Jeffrey Kirshner, MD); University of California at San Francisco, San Francisco, Calif (Alan P. Venook, MD); University of Chicago, Chicago, Ill (Gini Fleming, MD); University of Minnesota, Minneapolis, Minn (Bruce A. Peterson, MD); University of Nebraska Medical Center, Omaha, Neb (Anne Kessinger, MD); University of North Carolina at Chapel Hill, Chapel Hill, NC (Thomas Shea, MD); Vermont Cancer Center, Burlington, VT (Hyman B. Muss, MD); Wake Forest University School of Medicine, Winston-Salem, NC (David D. Hurd, MD); Washington University School of Medicine, St. Louis, Mo (Nancy L. Bartlett, MD); and Western Pennsylvania Hospital, Pittsburgh, Pa (Richard Shadduck, MD).
The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.
- Issue online: 20 JAN 2011
- Version of Record online: 22 SEP 2010
- Manuscript Accepted: 12 APR 2010
- Manuscript Revised: 7 APR 2010
- Manuscript Received: 8 FEB 2010
- 5A phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer. 2003; 98: 2592-2598., , , et al.
- 7The biology of vascular endothelial growth factor. Endocrinology. 1997; 18: 1-22.,